Close
CDMO Safety Testing 2026
Novotech

Baxter in Manesar,Waluj and Alathur

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational...

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
- Advertisement -

Baxter in Manesar:

Baxter’s facility in Manesar, Gurgaon demonstrates excellence in manufacturing for the company’s Medication Delivery and Renal businesses, producing IV and PD solutions.

The 21,000 sq.m. facility in Manesar was constructed by Baxter in 2002. The campus is designed for critical processing of sterile parenteral products and includes a Chemistry Lab, Microbiology Lab, Calibration Lab along with a central warehouse and administrative offices. The site also includes critical batch mixing/compounding operations, and has specialized packaging capabilities. In 2003 and 2005 it won the Ecoprofit Certification for ‘Cleaner Production and Environment Management’ and was one of the first to be granted a license to manufacture under the revised Schedule M of the Drugs and Cosmetics Act. The plant has recently expanded in capacity and is also vertically integrated to manufacture plastic parts. It is ISO13485 certified, enabling it to manufacture CE grade devices and employs 450 personnel.

Baxter in Waluj :

Baxter’s facility in Waluj, Maharashtra manufactures Large Volume Parenterals. It uses state of the art Form-Fill-Seal technology. It is a Large Volume Infusion plant on the outskirts of Aurangabad, Maharashtra.

It has Modern Quality Control Laboratories & Support systems to ensure compliance with GMP Guidelines. The plant operates in a continuous cycle of Formulation, Filling, Terminal sterilization and Packing activities. The over 52,000 sq. m. facility employs around 128 employees and caters to both the domestic and export markets.

Baxter in Alathur :

Baxter’s facility in Alathur is located about 50 kilometers south of Chennai, Tamil Nadu. The plant manufactures Large Volume Parenterals using state of the art Form-Fill-Seal technology.

The plant has Modern Quality Control Laboratories & Support systems to ensure compliance with GMP Guidelines .The plant operates in a continuous cycle of Formulation, Filling, Terminal sterilization and Packing activities. The over 39,000 sq. m. facility employs around 114 employees and caters to both the domestic and export markets.

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational...

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »